Clinical evaluation interferons malignant melanoma evaluation interferons treatment malignant melanoma treatment advanced disease interferons sole agent combination agents Studies value interferons adjuvant therapy high-risk primary melanoma patients necessary results date Human interferon alpha low response rates sole agent combination cimetidine response rate Recombinant alpha interferons responses advanced melanomas combination cimetidine response rate Recombinant alpha interferons combination interferons cimetidine monoclonal antibodies cytotoxics small improvement response rates DTIC recombinant interferon objective response rates low toxicity maintenance quality life randomized trial DTIC sole agent combination treatment significance finding 